Progress toward the treatment of arthritis by gene therapy

Christopher H Evans, P. D. Robbins

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Gene therapy offers several novel advantages to the treatment of arthritis and other joint diseases. Therapeutic genes may be delivered locally to diseased joints or systemically to extra-articular locations using viral or non-viral vectors by ex vivo or in vivo strategies. Pre-clinical experiments with rabbits have demonstrated the utility of using a retrovirus to deliver the human interleukin-1 receptor antagonist to the synovial lining of joints. A human trial based on this principle has been approved by the Recombinant DNA Advisory Committee of NIH and should begin this year.

Original languageEnglish (US)
Pages (from-to)543-546
Number of pages4
JournalAnnals of Medicine
Volume27
Issue number5
DOIs
StatePublished - 1995
Externally publishedYes

Fingerprint

Joint Diseases
Genetic Therapy
Arthritis
Joints
Interleukin-1 Receptors
Recombinant DNA
Advisory Committees
Retroviridae
Rabbits
Therapeutics
Genes

Keywords

  • Arthritis
  • Gene therapy
  • Interleukin-1 receptor antagonist
  • Synovium

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Progress toward the treatment of arthritis by gene therapy. / Evans, Christopher H; Robbins, P. D.

In: Annals of Medicine, Vol. 27, No. 5, 1995, p. 543-546.

Research output: Contribution to journalArticle

@article{1d3dcd66c8d6432296be975bdade3cfb,
title = "Progress toward the treatment of arthritis by gene therapy",
abstract = "Gene therapy offers several novel advantages to the treatment of arthritis and other joint diseases. Therapeutic genes may be delivered locally to diseased joints or systemically to extra-articular locations using viral or non-viral vectors by ex vivo or in vivo strategies. Pre-clinical experiments with rabbits have demonstrated the utility of using a retrovirus to deliver the human interleukin-1 receptor antagonist to the synovial lining of joints. A human trial based on this principle has been approved by the Recombinant DNA Advisory Committee of NIH and should begin this year.",
keywords = "Arthritis, Gene therapy, Interleukin-1 receptor antagonist, Synovium",
author = "Evans, {Christopher H} and Robbins, {P. D.}",
year = "1995",
doi = "10.3109/07853899509002466",
language = "English (US)",
volume = "27",
pages = "543--546",
journal = "Annals of Medicine",
issn = "0785-3890",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Progress toward the treatment of arthritis by gene therapy

AU - Evans, Christopher H

AU - Robbins, P. D.

PY - 1995

Y1 - 1995

N2 - Gene therapy offers several novel advantages to the treatment of arthritis and other joint diseases. Therapeutic genes may be delivered locally to diseased joints or systemically to extra-articular locations using viral or non-viral vectors by ex vivo or in vivo strategies. Pre-clinical experiments with rabbits have demonstrated the utility of using a retrovirus to deliver the human interleukin-1 receptor antagonist to the synovial lining of joints. A human trial based on this principle has been approved by the Recombinant DNA Advisory Committee of NIH and should begin this year.

AB - Gene therapy offers several novel advantages to the treatment of arthritis and other joint diseases. Therapeutic genes may be delivered locally to diseased joints or systemically to extra-articular locations using viral or non-viral vectors by ex vivo or in vivo strategies. Pre-clinical experiments with rabbits have demonstrated the utility of using a retrovirus to deliver the human interleukin-1 receptor antagonist to the synovial lining of joints. A human trial based on this principle has been approved by the Recombinant DNA Advisory Committee of NIH and should begin this year.

KW - Arthritis

KW - Gene therapy

KW - Interleukin-1 receptor antagonist

KW - Synovium

UR - http://www.scopus.com/inward/record.url?scp=0028875066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028875066&partnerID=8YFLogxK

U2 - 10.3109/07853899509002466

DO - 10.3109/07853899509002466

M3 - Article

VL - 27

SP - 543

EP - 546

JO - Annals of Medicine

JF - Annals of Medicine

SN - 0785-3890

IS - 5

ER -